secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2026-06-03T11:30:16+00:00
Accession:  0001193125-26-254590
Event type: other_material
Sentiment:  negative
Materiality: 0.35
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO shareholders reject executive stock option exchange; approve non-executive program
--------------------------------------------------------------------------------

- At 2026 annual meeting, shareholders voted against executive stock option exchange: 21,021,531 against, 14,097,815 for.
- Shareholders approved non-executive stock option exchange: 26,352,456 for, 8,853,230 against. Company commenced program on June 3.
- Exchange offer runs June 3–July 1, 2026; eligible options must have exercise price ≥ $18.00.
- Directors elected: Jean Bennett, Jerry Karabelas, Daniel Tassé; PwC ratified as auditor; advisory say-on-pay approved.
- Program not expected to significantly change stock compensation expense.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/0001193125-26-254590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/rgnx-20260529.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-254590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer